Overview

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of the Sufentanil NanoTab PCA System/15 mcg to the Placebo Sufentanil NanoTab PCA System for the management of acute moderate to severe post-operative pain after open abdominal surgery.

Phase:

Phase 3

Details

Lead Sponsor:

AcelRx Pharmaceuticals, Inc.

Treatments:

Dsuvia
Sufentanil